Skip to main content
SpringerLink
Log in

Successful Treatment of Refractory Idiopathic Thrombocytopenic Purpura and Neutropenia with the Monoclonal Antibody, Rituximab

  • Case Report
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

We describe a 22-year-old male with idiopathic autoimmune thrombocytopenia whose diagnosis was made at age of eight. He underwent splenectomy at age ten and ITP recurred at age 21 with episodes of infection and severe neutropenia (absolute count around 170/μl). He showed no response to immunoglobulin, corticosteroids, danazol, cyclosporine and azathioprine. Anti-CD20 antibody was administered at a dose of 375 mg/m2 once a week for 2 weeks. After the second infusion of rituximab, the platelet count increased from 4,000 to 516,000/mm3 and neutrophils count raised from 180 to 545/mm3. The response improvement persisted during follow up for 9 months (neutrophil count 4,390/mm3). This observation indicates that B-cells may play a central role in the pathogenesis of ITN. Anti-CD20 antibody therapy may be an efficient treatment for the patients with chronic or recurrent ITN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Calderwood S, Blanchette V, Doyle J, Freedman J, Stroncek D, Zipursky A (1994) Idiopathic thrombocytopenia and neutropenia in childhood. Am J Pediatr Hematol Oncol 16(2):95–101

    PubMed  CAS  Google Scholar 

  2. George JN, El-Havake MA, Raskob GE (1995) Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331:207

    Google Scholar 

  3. Bussel JB (2000) Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. Semin Oncol 27(6 Suppl 12):91

    PubMed  CAS  Google Scholar 

  4. Saleh MN, Gutheil J, Moore M et al (2000) A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27(6 Suppl 12):99

    PubMed  CAS  Google Scholar 

  5. Perotta A, Sunneberg TA, Scott J et al (1999) Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Blood 94(Suppl 1):49a

    Google Scholar 

  6. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78(4):275–280

    Article  PubMed  CAS  Google Scholar 

  7. Peñalver FJ, Jiménez-Yuste V, Almagro M, Alvarez-Larrán A, Rodríguez L, Casado M, Gallur L, Giraldo P, Hernández R, Menor D, Rodríguez MJ, Caballero D, González R, Mayans J, Millán I, Cabrera JR (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol 85(6):400–406

    Article  PubMed  Google Scholar 

  8. Tanai C, Iki S, Nakahara F, Iijima K, Usuki K, Kuwana M, Urabe A (2004) Effective treatment with rituximab in a patient with refractory idiopathic thrombocytopenic purpura. Rinsho Ketsueki 45(11):1181–1186 (In Japanese)

    PubMed  Google Scholar 

  9. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98(4):952–957

    Article  PubMed  CAS  Google Scholar 

  10. Moschovi M, Trimis G, Pergantou H, Platokouki H, Vrachnou E, Tzortzatou-Stathopoulou F (2005) Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura. J Paediatr Child Health 41(7):384–386

    Article  PubMed  Google Scholar 

  11. Latifzadeh SZ, Entezari V (2006) Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report. Clin Appl Thromb Hemost 12:489

    Article  PubMed  CAS  Google Scholar 

  12. Faurschou M, Hasselbalch HC, Nielsen OJ (2001) Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 66(6):408

    Article  PubMed  CAS  Google Scholar 

  13. Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97(2):228–233

    PubMed  CAS  Google Scholar 

  14. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A (2003) Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 78(11):1340–1346

    Article  PubMed  CAS  Google Scholar 

  15. Capsoni F, Sarzi-Puttini P, Zanella A (2005) Primary and secondary autoimmune neutropenia. Arthritis Res Ther 7(5):208–214

    Article  PubMed  CAS  Google Scholar 

  16. Shastri KA, Logue GL (1993) Autoimmune neutropenia. Blood 81:1984–1995

    PubMed  CAS  Google Scholar 

  17. Killick SB, Marsh JC, Hale G, Waldmann H, Kelly SJ, Gordon-Smith EC (1997) Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 97:306–308. doi:10.1046/j.1365-2141.1997.612718.x

    Article  PubMed  CAS  Google Scholar 

  18. Marsh JC, Gordon-Smith EC (2001) CAMPATH-1H in the treatment of autoimmune cytopenias. Cytotherapy 3:189–195. doi:10.1080/146532401753174133

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Urmia University of Medical Sciences, Urmia, Iran

    Davood Maleki, Marije van der Meer & Melina Peyk Eghbal

Authors
  1. Davood Maleki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marije van der Meer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melina Peyk Eghbal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Davood Maleki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maleki, D., van der Meer, M. & Eghbal, M.P. Successful Treatment of Refractory Idiopathic Thrombocytopenic Purpura and Neutropenia with the Monoclonal Antibody, Rituximab. Indian J Hematol Blood Transfus 28, 114–116 (2012). https://doi.org/10.1007/s12288-011-0099-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-011-0099-6

Keywords

Search

Navigation